EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE)

Kyra O'Brien, Cameron Coykendall, Kristin Harkins, Xingmei Wang, Abigail Perelman, Megan Zhang, Jason Karlawish

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-01 · 12 (1)

DOI: 10.1002/trc2.70207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 13.03.2026. Verfasst von Kyra O'Brien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institute on Aging, University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Blood‐based Alzheimer's disease (AD) biomarkers are increasingly used in clinical care, but there are few real‐world studies of their clinical utility. We evaluated the impact of plasma phosphorylated tau at threonine 181 (p‐tau181) on the diagnosis and management of patients with cognitive impairment in a memory clinic. METHODS Dementia specialists referred patients for plasma p‐tau181 testing during clinical care. We used surveys and chart review to assess the impact of plasma p‐tau181 testing on clinical care and patient and care partner wellbeing. We assessed co‐primary outcomes of (1) change in diagnostic confidence before vs after testing, (2) change in diagnosis, and (3) change in management. A diagnosis or management change of greater than 30% was considered to be clinically significant. Secondary and exploratory outcomes included impact of plasma p‐tau181 testing on the use of additional diagnostics and impact on patient and care partner psychological wellbeing, health behaviors, and future planning. RESULTS One hundred patients completed plasma p‐tau181 testing; 81% had an elevated result, and 19% had a non‐elevated result. Clinician diagnostic confidence averaged 1.43 points higher after p‐tau181 testing (95% confidence interval [CI] 1.02 to 1.84, p < 0.0001). After testing, 27.7% (95% CI 18.9% to 36.4%, p = 0.31) of patients had a change in management and 17.2% of patients had a change in diagnosis – significantly lower than the 30% threshold (95% CI 9.5% to 24.9%, p = 0.004). Patients with elevated results were less likely to have a diagnosis changed after testing than those with non‐elevated results (OR 0.08 [95% CI 0.01 to 0.47], p = 0.005). A non‐elevated result was associated with decreased use of amyloid positron emission tomography (PET) (odds ratio [OR] 0.25 [95% CI 0.07 to 0.86], p = 0.028). Patients with an elevated result had higher anxiety at 2 to 3 months after disclosure ( p = 0.01). DISCUSSION Non‐elevated plasma p‐tau181 results impacted the diagnosis and use of amyloid PET imaging in a memory clinic. There was increased anxiety in patients after testing, affirming the need for post‐disclosure psychological support.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseblood‐based biomarkersclinical utilityp‐tau181

Autor:innen und Institutionen

  • Department of Neurology Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
  • Leonard Davis Institute of Health Economics University of Pennsylvania Philadelphia Pennsylvania USA.
  • Department of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
  • Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
  • Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
  • College of Arts and Sciences University of Pennsylvania Philadelphia Pennsylvania USA.

Förderung

  • Institute on Aging, University of Pennsylvania

Zitieren

APA

O'Brien, K., Coykendall, C., Harkins, K., Wang, X., Perelman, A., Zhang, M., & Karlawish, J. (2026). Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE). Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(1). https://doi.org/10.1002/trc2.70207

Vancouver

O'Brien K, Coykendall C, Harkins K, Wang X, Perelman A, Zhang M, et al. Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE). Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(1). doi:10.1002/trc2.70207

BibTeX
@article{OBrien2026,
  author = {O'Brien, Kyra and Coykendall, Cameron and Harkins, Kristin and Wang, Xingmei and Perelman, Abigail and Zhang, Megan and Karlawish, Jason},
  title = {Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE)},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2026},
  volume = {12},
  number = {1},
  doi = {10.1002/trc2.70207}
}
Kostenlos starten →